[1] A. Al-Araji and A. I. Mohammed, “Multiple sclerosis in Iraq: does it have the same features encountered in Western countries?,” J. Neurol. Sci., vol. 234, no. 1–2, pp. 67–71, 2005.
[2] M. F. Jalal, A. O. Hatem, and E. S. Al-Obeidy, “Human leukocyte antigen (HLA) typing in Iraqi patient with multiple sclerosis (MS),” in MULTIPLE SCLEROSIS JOURNAL, vol. 24, no. 2, pp. NP26–NP27, 2018.
[3] C. E. Condrat et al., “miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis,” Cells, vol. 9, no. 2, p. 276, 2020.
[4] J. A. Slota and S. A. Booth, “MicroRNAs in neuroinflammation: implications in disease pathogenesis, biomarker discovery and therapeutic applications,” Non-coding RNA, vol. 5, no. 2, p. 35, 2019.
[5] C. E. McCoy, “miR-155 dysregulation and therapeutic intervention in multiple sclerosis,” Regul. Inflamm. Signal. Heal. Dis., pp. 111–131, 2017.
[6] T. S. Assmann et al., “Polymorphisms in genes encoding miR-155 and miR-146a are associated with protection to type 1 diabetes mellitus,” Acta Diabetol., vol. 54, pp. 433–441, 2017.
[7] S. Pashangzadeh, M. Motallebnezhad, F. Vafashoar, A. Khalvandi, and N. Mojtabavi, “Implications the Role of miR-155 in the Pathogenesis of Autoimmune Diseases,” Front. Immunol., vol. 12, p. 669382, 2021.
[8] Z. Golshani, Z. Hojati, A. Sharifzadeh, V. Shaygannejad, and M. Jafarinia, “Genetic variation in intergenic and exonic miRNA sequence and risk of multiple sclerosis in the isfahan patients,” Iran. J. Allergy, Asthma Immunol., pp. 477–484, 2018.
[9] L. Zheng et al., “Lanthanum chloride causes neurotoxicity in rats by upregulating miR-124 expression and targeting PIK3CA to regulate the PI3K/Akt signaling pathway,” Biomed Res. Int., vol. 2020, 2020.
[10] A. Zenere et al., “Prominent epigenetic and transcriptomic changes in CD4+ and CD8+ T cells during and after pregnancy in women with multiple sclerosis and controls,” J. Neuroinflammation, vol. 20, no. 1, pp. 1–20, 2023.
[11] H. K. Hassoun et al., “Expert opinion on the pharmacological management of multiple sclerosis in women of childbearing age in Iraq,” Heliyon, 2023.
[12] K. Borziak and J. Finkelstein, “X-linked genetic risk factors that promote autoimmunity and dampen remyelination are associated with multiple sclerosis susceptibility,” Mult. Scler. Relat. Disord., vol. 66, p. 104065, 2022.
[13] H. A. Al-Hamadani, “The Role of Gender in Early Onset Relapsing Remitting Multiple Sclerosis,” Iraqi Postgrad. Med. J., vol. 14, no. 2, 2015.
[14] H. K. Hassoun, A. Al-Mahadawi, N. M. Sheaheed, S. M. Sami, A. Jamal, and Z. Allebban, “Epidemiology of multiple sclerosis in Iraq: retrospective review of 4355 cases and literature review,” Neurol. Res., vol. 44, no. 1, pp. 14–23, 2022.
[15] F. S. Hammood and B. J. Mohammed, “Genetic Identifications for Sample of Multiple Sclerosis Iraqi Patients,” Iraqi J. Biotechnol., vol. 21, no. 2, pp. 225–235, 2022.
[16] S. A. Abdulhameed and B. J. Mohammed, “The Relationship of Gene Expression between TNF and TNF-Like Cytokine 1A Genes in Sample of Multiple Sclerosis Iraqi Patients,” Iraqi J. Biotechnol., vol. 21, no. 2, pp. 88–95, 2022.
[17] M. Khademi et al., “Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers,” PLoS One, vol. 8, no. 5, p. e63172, 2013.
[18] M. A. Ali, O. G. Shaker, H. M. Eid, E. E. Mahmoud, E. M. Ezzat, and S. N. Gaber, “Relationship between miR‑155 and miR‑146a polymorphisms and susceptibility to multiple sclerosis in an Egyptian cohort,” Biomed. Reports, vol. 12, no. 5, pp. 276–284, 2020.
[19] S. R. Mohammed et al., “Impact of miR-155 (rs767649 A> T) and miR-146a (rs57095329 A> G) polymorphisms in System Lupus Erythematosus susceptibility in an Egyptian cohort.,” Eur. Rev. Med. Pharmacol. Sci., vol. 25, no. 3, 2021.
[20] R. Wang et al., “Association between genetic variants of microRNA‐21 and microRNA‐155 and systemic lupus erythematosus: A case‐control study from a Chinese population,” J. Clin. Lab. Anal., vol. 36, no. 7, p. e24518, 2022.
[21] K. Xie et al., “A functional variant in miR-155 regulation region contributes to lung cancer risk and survival,” Oncotarget, vol. 6, no. 40, p. 42781, 2015.
[22] J. Ji et al., “MiR-155 and its functional variant rs767649 contribute to the susceptibility and survival of hepatocellular carcinoma,” Oncotarget, vol. 7, no. 37, p. 60303, 2016.
[23] Z. A. Aljawadi, A. R. Al-Derzi, B. A. Abdul-Majeed, and A. M. Almahdawi, “MicroRNAs (20a, 146a, 155, and 145) expressions in a sample of Iraqi patients with multiple sclerosis,” J. Fac. Med. Baghdad, vol. 58, no. 4, pp. 371–377, 2016.
[24] W. W Kamphuis, C. Derada Troletti, A. Reijerkerk, I. A Romero, and H. E de Vries, “The blood-brain barrier in multiple sclerosis: microRNAs as key regulators,” CNS Neurol. Disord. Targets (Formerly Curr. Drug Targets-CNS Neurol. Disord., vol. 14, no. 2, pp. 157–167, 2015.
[25] B. Shademan, A. Nourazarian, M. Nikanfar, C. B. Avci, M. Hasanpour, and A. Isazadeh, “Investigation of the miRNA146a and miRNA155 gene expression levels in patients with multiple sclerosis,” J. Clin. Neurosci., vol. 78, pp. 189–193, 2020.
[26] V. Lyons, “The Role of miR-155 in Myeloid cells during Experimental Autoimmune Encephalomyelitis.” Trinity College Dublin Ireland, 2020.
[27] A. Junker et al., “MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47,” Brain, vol. 132, no. 12, pp. 3342–3352, 2009.
[28] D. Luo, J. Wang, X. Zhang, X. Rang, C. Xu, and J. Fu, “Identification and functional analysis of specific MS risk miRNAs and their target genes,” Mult. Scler. Relat. Disord., vol. 41, p. 102044, 2020.
[29] L. D. Ward and M. Kellis, “HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants,” Nucleic Acids Res., vol. 40, no. D1, pp. D930–D934, 2012.